Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Multiple Myeloma 21Leukemia, Myeloid, Acute 8Hodgkin Disease 8Recurrence 7Neoplasms 7Lymphoma 7Neoplasms, Plasma Cell 5Lymphoma, Large B-Cell, Diffuse 5Leukemia 5Carcinoma, Non-Small-Cell Lung 5Waldenstrom Macroglobulinemia 4Sezary Syndrome 4Prostatic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Mycosis Fungoides 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, Extranodal NK-T-Cell 4Immunoblastic Lymphadenopathy 4Breast Neoplasms 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Lymphocytic, Chronic, B-Cell 3Burkitt Lymphoma 3Advanced Solid Tumors 3Triple Negative Breast Neoplasms 2

Interventions

selinexor 1Panobinostat 1Daunorubicin 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Chromosome Aberrations × Panobinostat × Clear all
NCT01242774 2020-12-19

Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)

Novartis

Phase 1 Completed
46 enrolled
Other hematologic neoplasm

Chromosome Aberrations, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡